Post-Marketing Assessment of Immunogenicity and Safety of Unituxin™ in High-Risk Neuroblastoma Patients

This is a multi-center, non-randomized, open-label study in patients with high-risk
neuroblastoma to assess the immunogenicity, safety and tolerability of Unituxin combination
therapy. Patients enrolled in the study were prescribed Unituxin for the treatment of
high-risk neuroblastoma.

Inclusion Criteria:

- Patient has been diagnosed with high-risk neuroblastoma.

- Patient has been prescribed Unituxin and plans to start Unituxin therapy within 30
days of study entry.

- Patient must start Unituxin therapy no later than 200 days after Autologous Stem Cell
Transplantation (ASCT).

- Written informed consent / assent must be obtained in accordance with institutional
and ICH guidelines.

Exclusion Criteria:

- Patient has received prior anti-GD2 antibody therapy.

- Patient has participated in an investigational clinical trial with tumor therapeutic
intent within 30 days of informed consent.

- Patient underwent Autologous Stem Cell Transplantation (ASCT) more than 200 days
prior to receiving Unituxin therapy.